Switzerland· 68114001
Ponvory 20 mg, Filmtabletten
A ponesimod product containing ponesimodum, registered in Switzerland by Medius AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Ponesimod is registered in 11 of 19 countries.
Countries holding a registration under ATC L04AE04 (ponesimod), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Ponesimod · ATC L04AE04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Italyprice
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ponesimod costs, country by country.
Normalised to the WHO defined daily dose (20 mg), so markets compare like for like.
- Switzerland: $69.06 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Ponesimod · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- IT Italy$69.77
- CH Switzerland$69.06
The record
At a glance
Swissmedic (Switzerland)- Active substance
- ponesimodum
- Manufacturer
- Medius AG
- Country
- Switzerland (CH)
- ATC code
- L04AE04
- ATC class
- Ponesimod
- Defined daily dose
- 20 mg, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680681140016Blist 28 StkCHF 1074.9
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ponesimod in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPONVORYLaboratoires Juvisé Pharmaceuticals, Villeurbanne
- United StatesPONVORYVanda Pharmaceuticals Inc.
- FinlandPonvoryLaboratoires Juvise Pharmaceuticals
- FrancePONVORY 20 mg, comprimé pelliculéLABORATOIRES JUVISE PHARMACEUTICALS
- IrelandPonvory 20 mg film-coated tabletsLaboratoires Juvise Pharmaceuticals
- BelgiumPonvory 20 mgLaboratoires Juvise Pharmaceuticals
- NetherlandsPonvory 20 mg filmomhulde tablettenLaboratoires Juvise Pharmaceuticals
- NorwayPonvoryLABORATOIRES JUVISE PHARMACEUTICALS
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ponvory
- Liechtenstein · Ponvory
- Norway · Ponvory
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8e2fd1b9-1c59-492e-9bfe-c8d7c4d27de6 GET /v1/drugs/8e2fd1b9-1c59-492e-9bfe-c8d7c4d27de6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "ponesimodum 20 mg",
"valid_from": "2025-01-01",
"limitations": "[{\"description\":\"Behandlung von erwachsenen Patienten mit schubförmig rezidivierenden Formen der multiplen Sklerose (RRMS) mit aktiver Erkrankung, definiert durch klinische oder bildgebende Merkmale.<br>\\n<br>\\nErstverschreibung durch den Facharzt FMH für Neurologie.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-01-01\"}]",
"galenic_form": "Filmtabl 20 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2022-01-01",
"self_retention_pct": 10
}See everything about ponesimod.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.